2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

4:30PM-6:00PM: Abstract Number: 3094

Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3064

From Art to Science: A Mobile App for Point-of-Care Relevance Determination for the Musculoskeletal Exam

Education

4:30PM-6:00PM: Abstract Number: 3061

Future Challenges in Pediatric Rheumatology: The Role of Graduate Medical Education (GME)

Education

4:30PM-6:00PM: Abstract Number: 3099

Higher Prevalence and Severity of Coronary Atherosclerosis in Psa Patients

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

4:30PM-6:00PM: Abstract Number: 3059

Impact of a Musculoskeletal Training Program on Residents’ Evaluation, Diagnosis, and Treatment of Osteoporosis

Education

4:30PM-6:00PM: Abstract Number: 3072

Increased Platelet Reactivity in Gout: Relationship to Tophus Burden and Colchicine Use

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

4:30PM-6:00PM: Abstract Number: 3090

Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3063

Learning Rheumatology through Fellow-Generated Questions: The Rheumatology Image of the Week Project

Education

4:30PM-6:00PM: Abstract Number: 3101

Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3082

Macrophage Activation Syndrome Is Identified By Coagulopathy, Hyperferritinemia, Fever, and Cytopenia in Hospitalized Patients, Resulting in Poor Outcome

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3075

Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

4:30PM-6:00PM: Abstract Number: 3065

Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies

Epidemiology and Public Health II: Obesity, Cancer and Mortality

4:30PM-6:00PM: Abstract Number: 6L

Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3102

Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3073

Non-Additive Interaction of the Glucokinase Regulatory Protein and APOBEC1 Complementation Factor Loci with Alcohol Consumption to Influence the Risk of Gout

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].